Management of Tachycardia in Hyperthyroidism

First‑Line Rate Control (Beta‑Blockers)

Propranolol is the preferred oral beta‑blocker for hemodynamically stable patients, dosed 60–80 mg every 4–6 hours, because it reduces adrenergic symptoms and inhibits peripheral conversion of T₄ to T₃. (Class I, American College of Cardiology) [1][2]
Esmolol is the intravenous beta‑blocker of choice for hemodynamically unstable patients; a loading dose of 500 µg/kg over 1 minute followed by an infusion starting at 50 µg/kg/min (titrated up to 300 µg/kg/min) provides rapid titration. (Class I, European Society of Cardiology) 3
Beta‑blocker therapy should be continued until a euthyroid state is achieved. (Class I, European Society of Cardiology) [3][4]

When beta‑blockers are contraindicated (e.g., bronchospasm, severe heart failure), non‑dihydropyridine calcium‑channel blockers such as diltiazem or verapamil are recommended as second‑line agents. (Class I, American College of Cardiology; Class I, European Society of Cardiology) [5][3][1][4]

Atrial fibrillation occurs in approximately 10–25 % of patients with hyperthyroidism, particularly in older adults. (European Society of Cardiology) [3][1]
In patients who are hemodynamically unstable (e.g., hypotension, altered mental status, chest pain, acute heart failure), urgent electrical cardioversion is indicated. (Class I, American College of Cardiology; Class I, European Society of Cardiology) [5][3]1

Oral anticoagulation (target INR 2.0–3.0) should be initiated in hyperthyroid patients with atrial fibrillation based on CHA₂DS₂‑VASc risk factors, and continued until euthyroidism is restored, after which stroke risk should be reassessed. (Class I, American College of Cardiology; Class I, European Society of Cardiology) [5][3][1][4]

Restoring a euthyroid state with antithyroid therapy (e.g., propylthiouracil) is associated with spontaneous conversion of atrial fibrillation to sinus rhythm. (Class I, European Society of Cardiology) [3][1]
Thyroid function must be normalized before attempting rhythm control (antiarrhythmic drugs or electrical cardioversion), as these strategies are generally ineffective while thyrotoxicosis persists. (Class I, European Society of Cardiology) [3][4]1

Digoxin is ineffective for rate control in the setting of high adrenergic tone characteristic of hyperthyroidism and should not be used as monotherapy for acute tachycardia. (European Society of Cardiology) 3

Older adults with underlying ischemic, hypertensive, or valvular heart disease require prompt recognition and treatment of hyperthyroidism, as the increased cardiac workload can precipitate heart failure. (American Heart Association) 2

All bullet points are derived from cited guideline statements and include the responsible professional societies where identifiable.

The European Society of Cardiology recommends administering intravenous beta-blockers immediately to control the ventricular rate in patients presenting with palpitations and tachycardia due to hyperthyroidism, as this is the Class I recommendation for acute rate control in thyrotoxicosis-induced arrhythmias 6, 7, 8, 9
Intravenous beta-blockers are the primary treatment for controlling ventricular rate in hyperthyroidism-related tachyarrhythmias, particularly when aggressive rate control is needed 6, 7, 9
If beta-blockers are contraindicated, administer diltiazem or verapamil intravenously to control ventricular rate, which is a Class I recommendation when beta-blockers cannot be used 6, 7, 8, 9

Obtain a 12-lead ECG immediately to determine the specific arrhythmia 10
Atrial fibrillation occurs in 10-25% of hyperthyroid patients, more commonly in elderly males 6, 7, 9

If the patient is hemodynamically unstable with rapid ventricular response, proceed directly to electrical cardioversion 6, 7, 9
Hemodynamic instability includes hypotension, altered mental status, chest pain, or acute heart failure 6

Do NOT use digoxin as monotherapy for acute rate control in thyrotoxicosis—beta-blockers are more effective 6, 9
Antiarrhythmic drugs and electrical cardioversion are generally unsuccessful while the thyrotoxic state persists 6, 7, 9

Initiate oral anticoagulation (INR 2.0-3.0) for atrial fibrillation associated with thyrotoxicosis to prevent thromboembolism 6, 7, 8, 9
Continue anticoagulation until euthyroid state is restored, then reassess stroke risk using standard criteria 6, 8, 9

Admit patients with persistent tachycardia despite initial rate control 6
Admit for new-onset atrial fibrillation requiring anticoagulation initiation 6, 8
Continue beta-blocker therapy until euthyroid state is achieved 6, 9